Objective-To examine the efficacy, safety, and the pharmacokinetic profile of a bolus dose administration regimen of alteplase in the treatment of acute myocardial infarction.
Design-An open pilot study. Setting-District general hospital. Patients-33 suitable consecutive patients presenting within six hours of the onset of symptoms who satisfied the electrocardiographic criteria for acute myocardial infarction. Interventions-Two intravenous boluses of 35 mg alteplase, 30 minutes apart.
Main outcome measures-Angiographic coronary patency at 90 minutes and 24 hours. Plasma alteplase concentration-time profile and pharmacokinetic analysis. Results-Coronary patency at 90 minutes: 26 of 30 arteries (87%, 95% confidence interval (CI) 74-99%). Coronary patency at 24 hours: 24 of 29 arteries (83%, CI 69-97%). Mean (SD) plasma tissue plasminogen activator (t-PA) concentration reached (2117-8) and 4233-3 (2217-5) ng/ml within 10 minutes of each bolus and fell to 425 8 (288 3) nglml between boluses. The estimated peak concentrations at two minutes after boluses were 12 389 (8580) ng/ml and 10 811 (6802) ng/ml. The derived pharmacokinetic variables were volume of distribution 311 (1-89) 1, clearance 213 (9-3) 1/h, half life 5*9 (1'7) minutes.
Conclusions-This simple administration regimen achieved brief, high concentrations of plasma t-PA that were well tolerated. The The mean (SD) pretreatment plasma t-PA concentration (20-1 (4 3) ng/ml) was significantly higher than our laboratory normal (3-6
(1-3) ng/ml). It rose to 4434-8 (2117-8) ng/ml within ten minutes ofthe first bolus ofalteplase, fell to 425-8 (288-3) ng/ml before the second bolus, and rose again to a peak of 4233-3 (2217-5) ng/ml within 10 minutes of the second bolus (figure). Mean concentrations then fell rapidly and at four hours were about twice the pretreatment values (40-6 (28&6) ng/ml). After this t-PA concentrations were low, variable, and at approximately physiological values. This introduced considerable random variation in the pharmacokinetic fitting; therefore the data fitted were the baseline-subtracted concentrations confined to the four hour period after the administration of alteplase. This approach was adopted by others.'2 14 The individual declines in t-PA concentration were fitted to one, two, and three compartment pharmacokinetic models, but a satisfactory fit was obtained only with the one compartment model. The pharmacokinetic results derived from this model were volume of distribution 3-11 (1 89) 1 (coefficient of variation (CV) 35-6 (26-7)%), clearance 21L3 (9-3) 1/h (CV 14-1 (11-7)%) and half life 5 9 (1-7) min. The coefficients of variation are means (SD) of the coefficients of variation of the individual fitted data and express the quality of fit of the model (table 3 ). Using this model we estimated the plasma t-PA concentrations two minutes after the beginning of the intravenous boluses ofalteplase, as a measure ofthe peak concentra- whereas some workers studied patency others studied reperfusion, with a difference owing to sub-total coronary occlusion at presentation and spontaneous reperfusion. '7 Verstraete and coworkers showed patency rates of 61% at 75-90 minutes after treatment using 0 75 mg/kg of double chain rt-PA over 90 minutes. " The same group using a 40 mg infusion of double chain rt-PA over 90 minutes achieved a coronary patency rate of 66% at 90 minutes.'8 Topol and the TAMI group achieved a patency rate of 68% with 70 mg of rt-PA over 90 minutes and one of 79% with a high dose (1-5 mg/kg) of alteplase over four hours in conjunction with a high dose of heparin."l2' In TIMI I workers used 80 mg of double chain rt-PA over three hours and found a reperfusion rate of 56%.67 Williams et al used the same dose of 80 mg over three hours and found a similar reperfusion rate of 68%.8
Published reports of studies of bolus doses of alteplase are limited. Verstraete et al using single boluses of alteplase found that doses of 60 mg and 50 mg were associated with reperfusion rates at 90 minutes of 32% and 45% respectively, although a maximum dose of 70 mg achieved reperfusion in 72%.22 Khan et al evaluated four boluses of double-chain t-PA of 25 mg given over 60 minutes and showed recanalisation in 11 of 14 patients; they suggested that this regimen achieves coronary patency more rapidly.2' In our study, 70 mg divided into two boluses also achieved a high patency rate, and would be expected to be associated with fewer bleeding complications. 24 In a recent small study Smalling et al, used rapid intravenous infusion of a weight adjusted dose of alteplase, and a median dose of 145 mg. They reported a 90 minute patency rate of 84%, which was significantly higher than the control group who received a conventional three hour infusion of 100 mg.25 These results suggest that rapid administration of the thrombolytic agent achieves higher patency, and that it is the peak concentration of agent achieved that is important-an inference supported by our data.
The reported higher patency rates were achieved with higher weight adjusted doses of rt-PA. In our study the total dose of 70 mg alteplase represents a mean dose of 0-98 mg/kg. This contrasts with 1-5 mg/kg administered by Topol et aP20 and the fixed doses of 150 mg used in the TIMI II study24 or 100 mg used in the Australian National Heart Foundation Study. 26 The 100 mg dose is recommended by the manufacturers27 and is now in regular use. Despite the lower dose we used, our patency rate of 87% at 90 minutes compares favourably with the published data.
Pharmacokinetic analysis of the plasma t-PA concentration-time profile after this bolus administration regimen of alteplase shows that very high, short lived concentrations of t-PA are achieved shortly after injection of the drug. The concentration of t-PA achieved at 10 minutes (4434-8 (2117-8) ng/ml is 34% higher than the peak concentration attained by Seifried et al, with 100 mg of single chain rt-PA delivered as a 10 mg bolus and 90 minute tapered infusion.'4 We found t-PA concentrations in excess of 2 300 ng/ml in all our patients and predicted concentrations two minutes after the boluses of alteplase in excess of 10 000 ng/ml. As would be expected, the period during which t-PA concentration was in excess of 1000 ng/ml is shorter with bolus administration than with prolonged infusion.
Despite Our findings confirm the rapid clearance of t-PA from the circulation, with a half life of 5 9 (1.7) minutes and modest inter-patient variability. These closely correlate with previous reports in patients, although they are somewhat slower than findings in normal volunteers with a lower total dose-possibly reflecting diminished cardiac output and hepatic blood flow in our patients with myocardial infarction. Our estimate of volume of distribution of 3-1 (1-9) 1 is very similar to previous estimates in both patients and volunteers.
Some workers have found a dose related rise in bleeding complications, in particular intracranial bleeding.24 In our study, using a relatively small dose of alteplase, we saw bleeding complications in eight (24%) of33, with five of these being related to arterial access for coronary angiography; there were three episodes of minor gastrointestinal bleeding (9%). No patients required transfusion or specific intervention. These results are similar to previously published data,69 0 but our small study numbers do not allow firm conclusions to be drawn.
Our findings show that alteplase administered as two intravenous boluses of 35 mg 30 minutes apart reliably produced very high concentrations of t-PA in the plasma, which was rapidly cleared from the circulation and allowed a high coronary patency rate in acute myocardial infarction. The total dose administered was less than that used in many studies reporting high patency, yet reocclusion rates were similar to those reported before. The greater simplicity of administration and higher efficacy of this regimen may allow alteplase treatment to be safely started before admission to hospital with the advantages that such earlier administration would give.
